ScreenerHero

CRDF Cardiff Oncology, Inc.

NAS · US · Healthcare · Biotechnology · cardiffoncology.com
1.090USD+1.87%Mkt Cap: 84.80M $P/E: —

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap84.80M USD
Enterprise Value49.18M USD
Revenue (TTM)508.00K USD
Gross Profit-34.82M USD
Net Income (TTM)-45.85M USD
Revenue/Share0.0070 USD
Last Price1.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees30
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.00
PEG—
EV/EBITDA-1.17
EV/Revenue96.81
P/S163.86
P/B2.76
EPS (TTM)-0.56
EPS (Forward)-0.54
52W Range
0.756613% of range3.310
52W High3.310 USD
52W Low0.7566 USD
Profitability
Gross Margin0.00%
Oper. Margin-9245.19%
EBITDA Margin0.00%
Profit Margin-7732.04%
ROE-101.02%
ROA-74.09%
Growth
Revenue Growth-14.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.92M USD
CapEx (TTM)44.00K USD
FCF Margin-4784.30%
FCF Yield-28.66%
Net Debt-34.06M USD
Net Debt/EBITDA0.81
Balance Sheet
Debt/Equity0.02
Current Ratio3.30
Quick Ratio3.21
Book Value/Sh0.39 USD
Cash/Share0.44 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateFeb 20, 2019
Splits
Last Split1:6
Split DateFeb 20, 2019
Analyst Consensus
Rating—
Target (Mean)5.814 USD
Upside (mean)+433.4%
Target Range1.200 USD – 12.00 USD
1.200+433.4% to mean12.00
# Analysts7
Ownership
Shares Out.77.80M
Float75.38M
Insiders6.20%
Institutions22.12%
Short Interest
Short Ratio14.8d
Short % Float16.15%
Short % Out.15.82%
Shares Short12.31M
Short (prev mo.)11.90M
Technical
SMA 501.073 (+1.6%)
SMA 2001.613 (-32.4%)
Beta1.42
S&P 52W Chg16.45%
Avg Vol (30d)673.15K
Avg Vol (10d)480.76K
Technical Indicators
RSI (14)43.7
MACD0.0071
MACD Signal0.0359
MACD Hist.-0.0288
BB Upper1.420 USD
BB Middle1.216 USD
BB Lower1.011 USD
BB Width33.57%
ATR (14)0.0766 USD
Vol Ratio (20d)0.68x